

L Number	Hits	Search Text	DB	Time stamp
1	54180	polysaccharide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:45
2	8944	polysaccharide and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:46
3	1052	(polysaccharide and cross-link\$) and polyamine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
4	328	((polysaccharide and cross-link\$) and polyamine) and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
5	94	((polysaccharide and cross-link\$) and polyamine) and carboxy) and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
6	6568	polysaccharide and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
7	2134	(polysaccharide and carboxy) and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
8	476	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
9	0	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronicl4 and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
10	80	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
11	67	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and chitin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
12	535	536/21	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
13	94	536/21 and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
14	27	(536/21 and cross-link\$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18

15	6	((536/21 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:22
16	2833	514/54	USPÄT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:23
17	522	514/54 and cross-link\$	USPÄT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:23
18	192	(514/54 and cross-link\$) and hyaluronic	USPÄT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:23
19	24	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPÄT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:23

L Number	Hits	Search Text	DB	Time stamp
1	54180	polysaccharide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:45
2	8944	polysaccharide and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:46
3	1052	(polysaccharide and cross-link\$) and polyamine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
4	328	((polysaccharide and cross-link\$) and polyamine) and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
5	94	((polysaccharide and cross-link\$) and polyamine) and carboxy) and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
6	6568	polysaccharide and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
7	2134	(polysaccharide and carboxy) and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
8	476	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
9	0	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic14 and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
10	80	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
11	67	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and chitin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
12	535	536/21	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
13	94	536/21 and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
14	27	(536/21 and cross-link\$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18

15	6	((536/21 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:22
16	2833	514/54	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:23
17	522	514/54 and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:23
18	192	(514/54 and cross-link\$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:23
19	24	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:49
20	0	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and complex?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:49
21	130	((514/54 and cross-link\$) and hyaluronic) and comple?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:50
22	57	((514/54 and cross-link\$) and hyaluronic) and comple?) and (copper or iron)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:52
23	76	((((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic) and (copper or iron or metal or ion)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:58
24	5	((514/54 and cross-link\$) and hyaluronic) and comple?) and salified	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:58
25	3	((((514/54 and cross-link\$) and hyaluronic) and comple?) and salified) and (copper or iron or zinc)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:33
26	22	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:00
27	0	((((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and trioxide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:00
28	30951	((((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and sulfur trioxide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:01

29	2	((((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:04
30	0	((((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:04
31	5	((536/21 and cross-link\$) and hyaluronic) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:06
32	3	((536/21 and cross-link\$) and hyaluronic) and sulfation) and pyridine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:06
33	1	((514/54 and cross-link\$) and hyaluronic) and complex?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:34
34	1	((514/54 and cross-link\$) and hyaluronic) and complex?) and (copper or zinc or iron)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:36
35	0	((((514/54 and cross-link\$) and hyaluronic) and complex?) and (copper or zinc or iron)) and cross-link?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 15:36

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:30:46 ON 23 SEP 2002

=> file polymers
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BABS' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 14:31:14 ON 23 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:31:14 ON 23 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'DKILIT' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'IFIPAT' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'PASCAL' ENTERED AT 14:31:14 ON 23 SEP 2002

Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 14:31:14 ON 23 SEP 2002

Copyright (C) 2002 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TEXTILETECH' ENTERED AT 14:31:14 ON 23 SEP 2002

COPYRIGHT (C) 2002 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 14:31:14 ON 23 SEP 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:31:14 ON 23 SEP 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 14:31:14 ON 23 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s polysaccharide
L1 218150 POLYSACCHARIDE

=> s l1 and carboxy
L2 7277 L1 AND CARBOXY

=> s l2 and activat?
L3 3796 L2 AND ACTIVAT?

=> s l3 and cross-link
L4 317 L3 AND CROSS-LINK

=> s l4 and (diamine or polyamine)
L5 76 L4 AND (DIAMINE OR POLYAMINE)

=> s l5 and hyaluroni
L6 0 L5 AND HYALURONI

=> s l5 and hyaluronic
L7 24 L5 AND HYALURONIC

=> dis l7 1-24 bib abs

L7 ANSWER 1 OF 24 USPATFULL
AN 2002:235521 USPATFULL
TI Process for ex vivo formation of mammalian bone and uses thereof
IN Kale, Sujata, Boston, MA, UNITED STATES
Long, Michael W., Northville, MI, UNITED STATES
PI US 2002127711 A1 20020912
AI US 2000-753043 A1 20001227 (9)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, Fulbright & Jaworski L.L.P., 600 Congress Avenue
Suite 2400, Austin, TX, 78701
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3032
AB The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.

L7 ANSWER 2 OF 24 USPATFULL
AN 2002:224605 USPATFULL
TI Lipid soluble steroid prodrugs
IN Unger, Evan C., Tucson, AZ, United States
Shen, DeKang, Tucson, AZ, United States
PA Imarx Therapeutics, Inc., Tucson, AZ, United States (U.S. corporation)
PI US 6444660 B1 20020903
AI US 2000-496761 20000203 (9)

RLI Division of Ser. No. US 1997-851780, filed on 6 May 1997, now patented,
Pat. No. US 6090800
DT Utility
FS GRANTED
EXNAM Primary Examiner: Badio, Barbara P.
LREP Woodcock Washburn LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6452
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel lipid soluble steroid
prodrugs, compositions comprising steroid prodrugs, and uses of the
same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 24 USPATFULL
AN 2002:217089 USPATFULL
TI Methods of using polynucleotide compositions
IN Kabanov, Alexander V., Omaha, NE, United States
Alakov, Valery Y., Montreal, CANADA
Vinogradov, Serguie, Omaha, NE, United States
PA Supratek Pharma Inc., CANADA (non-U.S. corporation)
PI US 6440743 B1 20020827
AI US 1999-320640 19990526 (9)
RLI Division of Ser. No. US 1998-124943, filed on 30 Jul 1998, now patented,
Pat. No. US 6221959 Continuation-in-part of Ser. No. US 1997-912968,
filed on 1 Aug 1997, now patented, Pat. No. US 6353055
Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994,
now patented, Pat. No. US 5656611
DT Utility
FS GRANTED
EXNAM Primary Examiner: McGarry, Sean; Assistant Examiner: Epps, Janet
LREP Mathews, Collins, Shepherd & McKay, P.A.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2206
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for stabilizing polynucleic acids and increasing the
ability of polynucleic acids to cross cell membranes and act in the
interior of a cell. In one aspect, the invention provides a
polynucleotide complex between a polynucleotide and certain polyether
block copolymers. The polynucleotide complex can further include a
polycationic polymer, as well as suitable targeting molecules and
surfactants. The invention also provides a polynucleotide complex
between a polynucleotide and a block copolymer comprising a polyether
block and a polycation block.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 24 USPATFULL
AN 2002:167866 USPATFULL
TI Acoustically active drug delivery systems
IN Unger, Evan C., Tucson, AZ, United States
PA Bristol-Myers Squibb Medical Imaging, Inc., Princeton, NJ, United States
(U.S. corporation)
PI US 6416740 B1 20020709
AI US 1998-75343 19980511 (9)
PRAI US 1997-46379P 19970513 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dudash, Diana; Assistant Examiner: Sharareh, Shahnam
LREP Woodcock Washburn LLP

CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 5660

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic delivery systems are also embodied by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperature below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted therapeutic delivery system, wherein said processing is selected from the group consisting of controlled agitation, controlled drying, and a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 24 USPATFULL
AN 2002:72457 USPATFULL
TI SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME
IN UNGER, EVAN C., TUCSON, AZ, UNITED STATES
PI US 2002039594 A1 20020404
AI US 1998-75477 A1 19980511 (9)
PRAI US 1997-46379P 19970513 (60)
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN KURTZ, MACKIEWICZ AND NORRIS, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 106
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5207

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a solvent and a surfactant in combination with a bioactive agent. The solvent and the surfactant may, if desired, form vesicles, an agglomeration of which comprises the matrix. The composition optionally comprises a gas or a gaseous precursor. The emulsion may be dried, and subsequently reconstituted in an aqueous or organic solution.

The present invention is also directed to a method of preparing a solid porous matrix comprising combining a solvent, a surfactant, and a therapeutic to form an emulsion; and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form a solid porous matrix. The resulting solid porous matrix may also comprise a gas or gaseous precursor and be added to a resuspending medium.

A method for the controlled delivery of a targeted therapeutic to a region of a patient is another embodiment of the present invention. The method comprises administering to the patient a composition having a solid porous matrix comprising a solvent, a surfactant, a therapeutic, and a gas or gaseous precursor, monitoring the composition using energy to determine the presence of the composition in the region; and releasing the therapeutic from the composition in the region using energy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 24 USPATFULL
AN 2002:57879 USPATFULL

TI Polynucleotide compositions for intramuscular administration
IN Lemieux, Pierre M., Ste.-Therese, CANADA
Kabanov, Alexander V., Omaha, NE, United States
Alakov, Valery Y., D'Urfe, CANADA
Vinogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma Inc., Doryal, United States (non-U.S. corporation)
PI US 6359054 B1 20020319
AI US 1999-227364 19990108 (9)
RLI Continuation-in-part of Ser. No. US 1998-124943, filed on 30 Jul 1998,
now patented, Pat. No. US 6221959 Continuation-in-part of Ser. No. US
1997-912968, filed on 1 Aug 1997 Continuation-in-part of Ser. No. US
1994-342209, filed on 18 Nov 1994, now patented, Pat. No. US 5656611
DT Utility
FS GRANTED
EXNAM Primary Examiner: Szekely, Peter
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for intramuscular administration of
polynucleotides, such as RNA, DNA, or derivatives thereof comprising
polynucleotides and block copolymers of alkylethers. The invention also
provides compositions and methods for stabilizing polynucleic acids and
increasing the ability of polynucleic acids to cross cell membranes and
act in the interior of a cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 24 USPATFULL
AN 2002:45673 USPATFULL
TI Polynucleotide compositions
IN Kabanov, Alexander Victorovich, Omaha, NE, United States
Alakov, Valery Yulievich, D'Urfe, CANADA
Vingogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma Inc., Quebec, CANADA (non-U.S. corporation)
PI US 6353055 B1 20020305
AI US 1997-912968 19970801 (8)
RLI Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994,
now patented, Pat. No. US 5656611
DT Utility
FS GRANTED
EXNAM Primary Examiner: Szekely, Peter
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions for stabilizing polynucleic acids
and increasing the ability of polynucleic acids to cross cell membranes
and act in the interior of a cell. In one aspect, the invention provides
a polynucleotide complex between a polynucleotide and certain polyether
block copolymers. Preferably, the polynucleotide complex will further
include a polycationic polymer. The compositions can further include
suitable targeting molecules and surfactants. In another aspect, the
invention provides a polynucleotide complex between a polynucleotide and
a block copolymer comprising a polyether block and a polycation block.
In yet another aspect, the invention provides polynucleotides 10 that
have been covalently modified at their 5' or 3' end to attach a
polyether polymer segment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 24 USPATFULL
 AN 2002:37868 USPATFULL
 TI Methods and compositions for sealing tissue leaks
 IN Wilkie, James, Melrose, MA, UNITED STATES
 Rolke, James, Fitzwilliam, NH, UNITED STATES
 Burzio, Luis, Andover, MA, UNITED STATES
 Tammishetti, Shekharam, Secunderabad, INDIA
 Pendharkar, Sanyog Manohar, Oldbridge, NJ, UNITED STATES
 PI US 2002022588 A1 20020221
 AI US 2000-747293 A1 20001222 (9)
 RLI Continuation-in-part of Ser. No. WO 1999-US14232, filed on 23 Jun 1999,
 UNKNOWN
 PRAI US 1998-90609P 19980623 (60)
 US 2000-199469P 20000425 (60)
 US 1999-171859P 19991222 (60)
 DT Utility
 FS APPLICATION
 LREP TESTA, HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET,
 BOSTON, MA, 02110
 CLMN Number of Claims: 167
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2885

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods and compositions that are useful for
 adhering biological and/or synthetic tissues, sealing fluid and/or
 gaseous leaks in biological and/or synthetic tissues, and preparing
 implants useful for delivery of a bioactive molecule such as a drug, for
 bulking applications, or for tissue prostheses. The present invention
 also relates to bio-erodable adhesive or occluding compositions and
 methods of using the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 24 USPATFULL
 AN 2002:22133 USPATFULL
 TI Novel drosophila tumor necrosis factor class molecule ("DmTNF") and
 variants thereof
 IN Carroll, Pamela M., Princeton, NJ, UNITED STATES
 Chen, Jian, Princeton, NJ, UNITED STATES
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
 Xiao, Hong, Princeton Junction, NJ, UNITED STATES
 Guan, Bo, Princeton, NJ, UNITED STATES
 Bowen, Michael A., Lawrenceville, NJ, UNITED STATES
 PI US 2002012968 A1 20020131
 AI US 2001-813329 A1 20010320 (9)
 PRAI US 2000-190816P 20000321 (60)
 DT Utility
 FS APPLICATION
 LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
 BOX 4000, PRINCETON, NJ, 08543-4000
 CLMN Number of Claims: 40
 ECL Exemplary Claim: 1
 DRWN 18 Drawing Page(s)
 LN.CNT 9244

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding Drosophila
 DmTNF polypeptides, fragments and homologs thereof. The present
 invention also is directed to novel polynucleotides encoding two
 Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments
 and homologs thereof. Also provided are vectors, host cells, antibodies,
 and recombinant and synthetic methods for producing said polypeptides.
 The invention further relates to screening methods for identifying
 agonists and antagonists of the polynucleotides and polypeptides of the
 present invention, in addition to methods of genetically modifying

Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 24 USPATFULL
AN 2001:234992 USPATFULL
TI Nanogel networks and biological agent compositions thereof
IN Kabanov, Alexander V., Omaha, NE, United States
Vinogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma, Inc., Canada (non-U.S. corporation)
PI US 6333051 B1 20011225
AI US 1998-146651 19980903 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2246

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Copolymer networks having at least one cross-linked **polyamine** polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 24 USPATFULL
AN 2001:182086 USPATFULL
TI Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions
IN Unger, Evan C., Tucson, AZ, United States
PA ImaRx Pharmaceutical Corp. (U.S. corporation)
PI US 2001031243 A1 20011018
AI US 2001-813484 A1 20010321 (9)
RLI Division of Ser. No. US 1997-929847, filed on 15 Sep 1997, PENDING
DT Utility
FS APPLICATION
LREP Woodcock Washburn Kurtz, Mackiewicz & Norris LLP, 46th Floor, One Liberty Place, Philadelphia, PA, 19103
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6360

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled compositions to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 24 USPATFULL
AN 2001:167740 USPATFULL
TI Composition for treating benign prostatic hypertrophy

IN Gokcen, Muharrem, Minneapolis, MN, United States
Guy, Terry J., Chaska, MN, United States
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)
PI US 6296847 B1 20011002
AI US 1993-154158 19931117 (8)
RLI Continuation of Ser. No. US 1991-707662, filed on 30 May 1991, now
abandoned Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989,
now abandoned Continuation-in-part of Ser. No. US 1989-303809, filed on
27 Jan 1989, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Witz, Jean C.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3351

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a composition and method for treating benign
prostatic hypertrophy in mammals so as to cause the dissolution and
regression of hypertrophied prostatic tissue and thereby provide relief
from the obstructive symptoms associated with the disease. The present
composition preferably comprises a sterile pyrogen-free solution of the
hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant,
and an antibiotic; all provided, in a pharmaceutically acceptable,
buffered, isotonic, aqueous carrier. The present method preferably
comprises the direct intraprostatic injection of a safe and
therapeutically effective dose of the composition via the transurethral
route of administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 24 USPATFULL
AN 2001:144937 USPATFULL
TI Solid matrix therapeutic compositions
IN Unger, Evan C., Tucson, AZ, United States
PA ImaRx Therapeutics, Inc. (U.S. corporation)
PI US 2001018072 A1 20010830
AI US 2001-828762 A1 20010409 (9)
RLI Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING
PRAI US 1997-46379P 19970513 (60)
DT Utility
FS APPLICATION
LREP Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia,
PA, 19103
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a
surfactant in combination with a bioactive agent. The solid porous
matrix may be prepared by combining a surfactant and a therapeutic,
together with a solvent, to form an emulsion containing random
aggregates of the surfactant and the therapeutic, and processing the
emulsion by controlled drying, or controlled agitation and controlled
drying to form the solid porous matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 24 USPATFULL
AN 2001:130897 USPATFULL
TI Prolonged release of GM-CSF
IN Gombotz, Wayne R., Kirkland, WA, United States
Pettit, Dean K., Seattle, WA, United States

Pankey, Susan C., Yardley, PA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6274175 B1 20010814
AI US 1999-442370 19991117 (9)
RLI Continuation of Ser. No. US 1998-185213, filed on 3 Nov 1998, now
patented, Pat. No. US 6120807 Division of Ser. No. US 1995-542445, filed
on 12 Oct 1995, now patented, Pat. No. US 5942253
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A
LREP Sheiness, Diana K.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations for controlled, prolonged release of GM-CSF have been
developed. These are based on solid microparticles formed of the
combination of biodegradable, synthetic polymers such as poly(lactic
acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with
excipients and drug loadings that yield zero order or first order
release, or multiphasic release over a period of approximately three to
twenty one days, preferably one week, when administered by injection. In
the preferred embodiment, the microparticles are microspheres having
diameters in the range of 10 to 60 microns, formed of a blend of PLGA
having different molecular weights, most preferably 6,000, 30,000 and
41,000. Other embodiments have been developed to alter the release
kinetics or the manner in which the drug is distributed in vivo. For
example, in some cases a polymer is selected which elicits a mild
inflammatory reaction, for example, PLGA and polyanhydrides can act as
chemoattractant, either due to the polymer itself or minor contaminants
in the polymer, or polymers which are bioadhesive are used for
transmucosal or oral delivery. In another embodiment, the GM-CSF is
administered in a hydrogel which can be injected subcutaneous or at a
specific site for controlled release. The microparticles or hydrogel are
administered to the patient in an amount effect to stimulate
proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 24 USPATFULL
AN 2001:97899 USPATFULL
TI Autocross-linked **hyaluronic** acid and related pharmaceutical
compositions for the treatment of arthropathies
IN Bellini, Davide, Padua, Italy
Paparella, Annamaria, Bari, Italy
O'Regan, Michael, Padua, Italy
Callegaro, Lanfranco, Vicenza, Italy
PA Fidia, S.p.A., Abano Terme, Italy (non-U.S. corporation)
PI US 6251876 B1 20010626
WO 9749412 19971231
AI US 1999-202817 19990625 (9)
WO 1997-EP3238 19970620
19990625 PCT 371 date
19990625 PCT 102(e) date
PRAI IT 1996-PD163 19960621
DT Utility
FS GRANTED
EXNAM Primary Examiner: Peselev, Elli
LREP Birch, Stewart, Kolasch & Birch LLP, Svensson, Leonard R.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,2,8
DRWN 19 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions containing an autocross-linked form of **hyaluronic** acid as a first component in a mixture with a second component noncross-linked **hyaluronic** acid, and possibly also in combination with another pharmacologically active substance. These compositions can be used in the treatment of arthropathies due to their unique viscoelastic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 24 USPATFULL
AN 2001:59978 USPATFULL
TI Polynucleotide compositions
IN Kabanov, Alexander V., Omaha, NE, United States
Alakov, Valery Y., D'Urfe, Canada
Vinogradov, Sergey V., Omaha, NE, United States
PA Supratek Pharma, Inc., Montreal, Canada (non-U.S. corporation)
PI US 6221959 B1 20010424
AI US 1998-124943 19980730 (9)
RLI Continuation-in-part of Ser. No. US 1998-912968, filed on 1 Aug 1998
Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994,
now patented, Pat. No. US 5656611
DT Utility
FS Granted
EXNAM Primary Examiner: Michl, Paul R.
LREP Mathews, Collins, Shepherd & Gould, P.A.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. The polynucleotide complex can further include a polycationic polymer, as well as suitable targeting molecules and surfactants. The invention also provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 24 USPATFULL
AN 2000:124586 USPATFULL
TI Prolonged release of GM-CSF
IN Gombotz, Wayne, Kirkland, WA, United States
Pettit, Dean, Seattle, WA, United States
Pankey, Susan, Seattle, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6120807 20000919
AI US 1998-185213 19981103 (9)
RLI Division of Ser. No. US 1995-542445, filed on 12 Oct 1995, now patented,
Pat. No. US 5942253
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1382

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic

acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 24 USPATFULL
AN 2000:91955 USPATFULL
TI Lipid soluble steroid prodrugs
IN Unger, Evan C., Tucson, AZ, United States
Shen, DeKang, Tucson, AZ, United States
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6090800 20000718
AI US 1997-851780 19970506 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel lipid soluble steroid prodrugs compositions comprising steroid prodrugs, and uses of the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 24 USPATFULL
AN 2000:87694 USPATFULL
TI Compositions of microspheres for wound healing
IN Ritter, Vladimir, Kiriat-Yam, Israel
Ritter, Marina, Kiriat-Yam, Israel
PA Polyheal Ltd., Haifa, Israel (non-U.S. corporation)
PI US 6086863 20000711
AI US 1998-177954 19981023 (9)
RLI Continuation-in-part of Ser. No. US 1997-868950, filed on 4 Jun 1997, now patented, Pat. No. US 5861149
DT Utility
FS Granted
EXNAM Primary Examiner: Cintins, Marianne M.; Assistant Examiner: Kim, Vickie
LREP Graham & James LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 1659

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Therapeutic compositions of microspheres for application to wounds and/or lesions for accelerating wound healing and muscle regeneration. The microspheres are made up of non-biodegradable material having a

substantial surface charge. The therapeutic composition further includes a pharmaceutically acceptable carrier in which the microspheres are insoluble and a container for holding the composition. The therapeutic composition further contains pharmacologic agents or biologics that accelerate the wound healing process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 24 USPATFULL
AN 2000:21560 USPATFULL
TI Prodrugs comprising fluorinated amphiphiles
IN Unger, Evan C., Tucson, AZ, United States
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6028066 20000222
AI US 1997-887215 19970702 (8)
RLI Continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes, inter alia, novel prodrugs comprising fluorinated amphiphiles, compositions comprising the novel prodrugs, and methods of use of the prodrugs and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 24 USPATFULL
AN 1999:99401 USPATFULL
TI Prolonged release of GM-CSF
IN Gombotz, Wayne, Kirkland, WA, United States
Pettit, Dean, Seattle, WA, United States
Pankey, Susan, Seattle, WA, United States
Lawter, James Ronald, Goshen, NY, United States
Huang, W. James, Sommerville, NJ, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
American Cyanamid Company, Pearl River, NY, United States (U.S. corporation)
PI US 5942253 19990824
AI US 1995-542445 19951012 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For

example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 24 USPATFULL
AN 1998:75722 USPATFULL
TI Products comprising substrates capable of enzymatic cross-linking
IN Cappello, Joseph, San Diego, CA, United States
PA Protein Polymer Technologies, San Diego, CA, United States (U.S. corporation)
PI US 5773577 19980630
AI US 1995-397633 19950302 (8)
RLI Continuation-in-part of Ser. No. US 1994-205518, filed on 3 Mar 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner: Stole, Einar
LREP Trecartin, Richard F.Flehr Hohbach Test Albritton & Herbert LLP
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3006

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymers are provided comprising protein polymers comprising blocks of repeating units and sequences comprising amino acids, individually or in defined sequences, capable of enzyme catalyzed covalent bond formation for cross-linking, as exemplified by glutamine and/or lysine reactive for FXIII catalyzed isopeptide formation or non-amino acid polymers having side chains comprising such amino acids or sequences, which may be used for preparation of articles of manufacture, particularly cross-linkable compositions. By appropriate choice of the polymer, resorbable implantable polymers may be used in internal applications for mammals as formed objects or depots.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 24 USPATFULL
AN 97:93905 USPATFULL
TI Crosslinked **carboxy polysaccharides**
IN Della Valle, Francesco, Padua, Italy
Romeo, Aurelio, Rome, Italy
PA Fidia, S.p.A., Abano Terme, Italy (non-U.S. corporation)
PI US 5676964 19971014
AI US 1995-465055 19950605 (8)
RLI Continuation of Ser. No. US 1993-70505, filed on 1 Jun 1993 which is a continuation of Ser. No. US 1989-350919, filed on 12 May 1989, now abandoned
PRAI IT 1988-47964 19880513
DT Utility
FS Granted
EXNAM Primary Examiner: Peselev, Elli
LREP Birch, Stewart, Kolasch & Birch, LLP
CLMN Number of Claims: 65
ECL Exemplary Claim: 1,36
DRWN No Drawings
LN.CNT 2523

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inter and/or intramolecular cross-linked esters of acid **polysaccharides** are disclosed in which a part or all of the **carboxy** groups are esterified with hydroxyl groups of the same molecule and/or of different molecules of the acid **polysaccharide**. These inner cross-linked esters of **polysaccharide** acids are useful in the field of biodegradable plastic materials, to manufacture sanitary and surgical articles, in the cosmetic and pharmaceutical fields, in the food industry and in many other industrial fields.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 24 USPATFULL
AN 92:42541 USPATFULL
TI Method for treating benign prostatic hypertrophy
IN Gokcen, Muharrem, Minneapolis, MN, United States
Guy, Terry J., Chaska, MN, United States
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)
PI US 5116615 19920526
AI US 1991-707628 19910530 (7)
RLI Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-303809, filed on 27 Jan 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Stone, Jacqueline
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a composition and method for treating benign prostatic hypertrophy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 14:30:46 ON 23 SEP 2002)

FILE 'BABS, CAPLUS, CBNB, CEN, CIN, DKILIT, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPINDEX, WTEXTILES' ENTERED AT 14:31:14 ON 23 SEP 2002

L1 218150 S POLYSACCHARIDE
L2 7277 S L1 AND CARBOXY
L3 3796 S L2 AND ACTIVAT?
L4 317 S L3 AND CROSS-LINK
L5 76 S L4 AND (DIAMINE OR POLYAMINE)
L6 0 S L5 AND HYALURONI
L7 24 S L5 AND HYALURONIC

=> s l7 and sulfation

L8 1 L7 AND SULFATION

=> dis 18 bib abs

L8 ANSWER 1 OF 1 USPATFULL
AN 2002:22133 USPATFULL
TI Novel drosophila tumor necrosis factor class molecule ("DmTNF") and
variants thereof
IN Carroll, Pamela M., Princeton, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Xiao, Hong, Princeton Junction, NJ, UNITED STATES
Guan, Bo, Princeton, NJ, UNITED STATES
Bowen, Michael A., Lawrenceville, NJ, UNITED STATES
PI US 2002012968 A1 20020131
AI US 2001-813329 A1 20010320 (9)
PRAI US 2000-190816P 20000321 (60)
DT Utility
FS APPLICATION
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 9244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding Drosophila
DmTNF polypeptides, fragments and homologs thereof. The present
invention also is directed to novel polynucleotides encoding two
Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments
and homologs thereof. Also provided are vectors, host cells, antibodies,
and recombinant and synthetic methods for producing said polypeptides.
The invention further relates to screening methods for identifying
agonists and antagonists of the polynucleotides and polypeptides of the
present invention, in addition to methods of genetically modifying
Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1,
or DmTNFv2. The invention also relates to the use of such modified
insects or cells to characterize DmTNF activity, identify TNF-like genes
and/or genes implicated in modulating TNF, characterize TNF signaling
pathways, and/or to identify modulators of DmTNF activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file chemistry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	93.06	93.27

FILE 'AGRICOLA' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'ALUMINIUM' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUIRE' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 US Environmental Protection Agency (EPA)

FILE 'BABS' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'BIOCOMMERCE' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All
rights reserved

FILE 'BIOTECHNO' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CAOLD' ENTERED AT 14:36:29 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 14:36:29 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEABA-VTB' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 DECHEMA eV

FILE 'CEN' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CERAB' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CIN' ENTERED AT 14:36:29 ON 23 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 14:36:29 ON 23 SEP 2002
Compendex Compilation and Indexing (C) 2002
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'CONFSCI' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'COPPERLIT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Copper Development Association Inc. (CDA)

FILE 'CORROSION' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'DKILIT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'ENCOMPLIT' ENTERED AT 14:36:29 ON 23 SEP 2002
EnComplit compilation and indexing (C) 2002
Elsevier Engineering Information Inc. All rights reserved.

FILE 'ENCOMPLIT2' ENTERED AT 14:36:29 ON 23 SEP 2002
EnComplit2 compilation and indexing (C) 2002
Elsevier Engineering Information Inc. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'GENBANK' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'INSPEC' ENTERED AT 14:36:29 ON 23 SEP 2002
Compiled and produced by the IEE in association with FIZ KARLSRUHE

COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INSPHYS' ENTERED AT 14:36:29 ON 23 SEP 2002
Compiled and produced by the IEE in association with FIZ KARLSRUHE
COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INVESTEXT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'IPA' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'METADEX' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (c) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'NAPRALERT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NIOSHTIC' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:36:29 ON 23 SEP 2002
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2002)

FILE 'PAPERCHEM2' ENTERED AT 14:36:29 ON 23 SEP 2002
Paperchem2 compilation and indexing (C) 2002
Elsevier Engineering Information Inc. All rights reserved.

FILE 'PASCAL' ENTERED AT 14:36:29 ON 23 SEP 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'RUSSCI' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Andrigal Ltd.

FILE 'SCISEARCH' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TULSA' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'USAN' ENTERED AT 14:36:29 ON 23 SEP 2002
COPYRIGHT (C) 2002 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'WELDASEARCH' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (c) 2002 The Welding Institute (TWI)

FILE 'WSCA' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 PAINT RESEARCH

=> s polysaccharide

L9 239171 POLYSACCHARIDE

=> s l9 and carboxy

L10 628 L9 AND CARBOXY

=> s l10 and activat?

26 FILES SEARCHED...

L11 40 L10 AND ACTIVAT?

=> s l11 and cross-link?

25 FILES SEARCHED...

L12 1 L11 AND CROSS-LINK?

=> dis l12 bib abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

AN 1990:406740 CAPLUS

DN 113:6740

TI Preparation of crosslinked **carboxy polysaccharides** as
biodegradable plastic materials for cosmetics and pharmaceuticals

IN Della Valle, Francesco; Romeo, Aurelio

PA Fidia S.p.A., Italy

SO Eur. Pat. Appl., 37 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 341745	A1	19891115	EP 1989-108630	19890512
	EP 341745	B1	19941214		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8910941	A1	19891116	WO 1989-EP519	19890512
	W: AU, DK, FI, HU, JP, KR				
	AU 8935747	A1	19891129	AU 1989-35747	19890512
	AU 631125	B2	19921119		
	HU 53666	A2	19901128	HU 1989-3636	19890512
	HU 210926	B	19950928		
	JP 02504163	T2	19901129	JP 1989-505458	19890512
	JP 2941324	B2	19990825		
	EP 614914	A2	19940914	EP 1994-108633	19890512
	EP 614914	A3	19941228		
	EP 614914	B1	20000816		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2064378	T3	19950201	ES 1989-108630	19890512
	IL 90274	A1	19960912	IL 1989-90274	19890512
	CA 1339122	A1	19970729	CA 1989-599557	19890512
	JP 10324701	A2	19981208	JP 1998-152832	19890512
	AT 195534	E	20000915	AT 1994-108633	19890512
	ES 2151910	T3	20010116	ES 1994-108633	19890512
	DK 9000109	A	19900312	DK 1990-109	19900112
	US 5676964	A	19971014	US 1995-465055	19950605
PRAI	IT 1988-47964	A	19880513		
	EP 1989-108630	A3	19890512		
	JP 1989-505458	A3	19890512		
	US 1989-350919	B1	19890512		
	WO 1989-EP519	A	19890512		
	US 1993-70505	A1	19930601		
AB	Inter- and/or intramol. esters of acid polysaccharides contg.				

carboxy functions (e.g. auto-crosslinked **polysaccharides**), wherein (1) a first portion or all of the **carboxy** groups are esterified with hydroxy groups of the same mol. and/or of different mols. of the acid **polysaccharide** and/or (2) a second portion of the **carboxy** groups are esterified with a mono- or polyvalent alcs. including various drugs (e.g. alkaloids, anesthetic, analgesic, antiinflammatory, antiviral, antibacterial, etc.) and optionally salified with an alkali or alk. earth metal, Mg, Al, or an amine including various drugs (e.g. alkaloids, peptides, antipsychotics, phenothiazine, vasoconstrictors, etc.), are prepd. by treating an acidic **polysaccharide** (e.g., hyaluronic acid, alginic acid, CM-cellulose, carboxymethylchitin) with an **activating** agent (e.g. 2-chloro-1-methylpyridinium iodide) and subjecting the resulting intermediate **activated polysaccharide** derivs. to heat or irradiation. These auto-crosslinked **polysaccharide** acids are useful in the field of biodegradable plastic materials to manuf. sanitary and surgical articles (e.g. surgical suture thread, film for artificial skin, and sponges for the medication of wounds and lesions), for pharmaceutical vehicles for controlled-release of drugs (capsules for the s.c. implantation of medicaments or microcapsules for s.c., i.m., or i.v. injection), etc.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	70.18	163.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 14:39:42 ON 23 SEP 2002

Research
DatabasesBasic
SearchAdvanced
SearchChoose
Databases

Keyword

Publications

MeSH

[New Search](#) | [View Folder](#) | [Preferences](#) | [Help](#)

US PATENT AND TRADEMARK OFFICE

Database: MEDLINE

Find:

Search

Folder has 0 items.

☒ Standard Search ☐ All Words ☐ Any Words ☐ Exact Phrase [Search Tips](#)

No results were found for your search query.

You may want to try your search again after following one or more of these tips:

- Check the spelling of your search terms. Correct any misspellings and re-run the search.
- To broaden your search, use the Boolean operator OR. For example, type: Siamese OR cats.

See [hints](#) for suggestions.

Search Options	Results
Limit your results:	
<div>Limiters Expanders Clear</div>	
Full Text <input type="checkbox"/>	
Date of Publication: Month <input type="text"/> Yr. <input type="text"/> to Month <input type="text"/> Yr. <input type="text"/>	
Author <input type="text"/>	
English Language <input type="checkbox"/>	
Review Articles <input type="checkbox"/>	
Human <input type="checkbox"/>	
Animal <input type="checkbox"/>	
Subset <input type="text"/>	
Publication Type <input type="text"/>	
Language(s) <input type="text"/>	
Gender <input type="text"/>	
Expand your search to:	
<div>Limiters Expanders Clear</div>	
Also search within the full text of the articles <input type="checkbox"/>	
Also search for related words <input type="checkbox"/>	

[Top of Page](#)© 2002 EBSCO Publishing. [Privacy Policy](#) - [Terms of Use](#)